162 related articles for article (PubMed ID: 16428940)
21. The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
Kohno N; Kitahara S; Tamura E; Tanabe T; Nakanoboh M; Kawada M; Shirasaka T
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():592-9. PubMed ID: 10895216
[TBL] [Abstract][Full Text] [Related]
22. [Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced nephrotoxicity].
Kubota A; Yoshida T; Tsukuda M; Furukawa S; Miyata K; Mochimatsu I; Sawaki S
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2599-605. PubMed ID: 2774590
[TBL] [Abstract][Full Text] [Related]
23. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
[TBL] [Abstract][Full Text] [Related]
24. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.
Bhat ZY; Cadnapaphornchai P; Ginsburg K; Sivagnanam M; Chopra S; Treadway CK; Lin HS; Yoo G; Sukari A; Doshi MD
PLoS One; 2015; 10(11):e0142225. PubMed ID: 26556481
[TBL] [Abstract][Full Text] [Related]
25. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
26. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
[TBL] [Abstract][Full Text] [Related]
27. Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.
Goren MP; Forastiere AA; Wright RK; Horowitz ME; Dodge RK; Kamen BA; Viar MJ; Pratt CB
Cancer Chemother Pharmacol; 1987; 19(1):57-60. PubMed ID: 2880677
[TBL] [Abstract][Full Text] [Related]
28. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center.
Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ
J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin and mitoguazone. An induction chemotherapy regimen in advanced head and neck cancer.
Forastiere AA; Perry DJ; Wolf GT; Wheeler RH; Natale RB
Cancer; 1988 Dec; 62(11):2304-8. PubMed ID: 3179946
[TBL] [Abstract][Full Text] [Related]
30. Evaluating dose of cisplatin responsible for causing nephrotoxicity.
Higuchi K; Yanagawa T
PLoS One; 2019; 14(4):e0215757. PubMed ID: 31022233
[TBL] [Abstract][Full Text] [Related]
31. Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity.
Sendur MA; Aksoy S; Yaman S; Arik Z; Tugba Kos F; Akinci MB; Civelek B; Yildirim Ozdemir N; Uncu D; Zengin N
J BUON; 2013; 18(1):274-80. PubMed ID: 23613416
[TBL] [Abstract][Full Text] [Related]
32. Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation.
Caglar K; Kinalp C; Arpaci F; Turan M; Saglam K; Ozturk B; Komurcu S; Yavuz I; Yenicesu M; Ozet A; Vural A
Nephrol Dial Transplant; 2002 Nov; 17(11):1931-5. PubMed ID: 12401849
[TBL] [Abstract][Full Text] [Related]
33. Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
Kohno N; Kitahara S; Tamura E; Tanabe T
Oncology; 2002; 63(3):226-31. PubMed ID: 12381901
[TBL] [Abstract][Full Text] [Related]
34. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M
Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810
[TBL] [Abstract][Full Text] [Related]
35. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
[TBL] [Abstract][Full Text] [Related]
36. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Taylor SG; Murthy AK; Vannetzel JM; Colin P; Dray M; Caldarelli DD; Shott S; Vokes E; Showel JL; Hutchinson JC
J Clin Oncol; 1994 Feb; 12(2):385-95. PubMed ID: 8113846
[TBL] [Abstract][Full Text] [Related]
37. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ
J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650
[TBL] [Abstract][Full Text] [Related]
38. [Effectiveness of concurrent chemoradiation therapy using TPF].
Yoshida T
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1244-9. PubMed ID: 20684090
[No Abstract] [Full Text] [Related]
39. Concurrent radiation therapy, 5-fluorouracil, and cisplatin for stage II, III, and IV, node-negative, squamous cell head and neck cancer. Results and surgical implications.
Adelstein DJ; Sharan VM; Damm C; Earle AS; Shah AC; Haria CD; Trey JE; Carter SG; Hines JD
Cancer; 1992 Dec; 70(11):2685-90. PubMed ID: 1423200
[TBL] [Abstract][Full Text] [Related]
40. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA;
J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
